BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for enGene Holdings Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-29 5:12 pm Sale |
2025-01-27 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 945,402 1.800% |
-2,106,037 (-69.02%) |
Filing |
| 2025-01-29 5:09 pm Sale |
2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 3,051,439 5.900% |
-145,000 (-4.54%) |
Filing |
| 2024-02-22 4:45 pm Unchanged |
2024-02-20 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 3,196,439 7.200% |
0 (Unchanged) |
Filing |
| 2023-11-13 4:45 pm Purchase |
2023-10-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 3,196,439 13.200% |
3,196,439 (New Position) |
Filing |